Pharmaceutical & Informed Consent Form Translation
An Informed Consent Form has to do two incompatible things at once. It is a regulatory instrument that an ethics committee will scrutinise clause by clause, and it is a plain-language document that a trial participant with no medical training has to genuinely understand before they sign it. Getting both right, in the same paragraph, in a language with no settled pharmaceutical vocabulary, is what pharmaceutical translation actually consists of.
The consequences of an error here are not commercial. A mistranslated dosage unit, a transposed risk percentage or a softened side-effect statement changes what a participant believes about their own safety. A single inaccurate term in a protocol can invalidate a study document during review. This is why our pharmaceutical work runs at our highest service tier by default, with no AI anywhere in the workflow.
What we translate
Each document type in this sector carries its own demands.
Informed Consent Forms (ICF)
Must satisfy an ethics committee and a layperson simultaneously. Reading level is a regulatory requirement, not a stylistic preference.
Clinical trial protocols
Randomisation, endpoints and inclusion criteria carry precise methodological meaning. A translator without research background will render them plausibly and wrongly.
Investigator brochures
Dense pharmacological content aimed at clinicians, requiring a different register from the participant-facing documents in the same study.
Case report forms (CRF)
Field labels and response options must map exactly across languages, or the collected data cannot be pooled across sites.
Regulatory submission dossiers
CTD, NDA and marketing authorisation documents where formatting and terminology are prescribed by the receiving authority.
Patient-reported outcome measures (PRO)
Validated instruments where the translation itself must be validated - linguistic validation and cognitive debriefing, not translation alone.
Patient information leaflets and labelling
Governed by market-specific labelling law, with mandated phrasing that cannot be translated freely.
What makes this sector different
The problems below are specific to this kind of content - they do not arise the same way in general translation work.
Translate the term, or transliterate it?
For each drug name, oncological term and procedure, the translator must choose between translating it, phonetically transliterating it, or using both. Translate a term with no established equivalent and the participant will not recognise it. Transliterate one that is unfamiliar in clinical literature and the ethics committee may flag it. There is no formula - it is a judgement made term by term, then applied consistently across every language file in the study.
Languages with no pharmaceutical vocabulary database
For several Indian and African languages there is simply no established pharmaceutical terminology resource to draw on. The glossary has to be built at the start of the project and enforced across every translator on it, because there is nothing authoritative to check against afterwards.
Numbers are not a linguistic problem
Risk percentages, dosages, measurements and reference ranges are verified digit by digit as a separate check. A transposed figure survives a purely linguistic proofread because the sentence still reads perfectly.
Reading level as a regulatory requirement
CDSCO and ICMR guidelines require participant-facing documents to be comprehensible to the participant. That constrains vocabulary and sentence structure in ways that pull directly against the legal precision the same document needs.
Consistency across parallel language teams
A study running in nine languages has nine specialist translators working simultaneously. Every terminology clarification raised by one has to reach all nine at once, or the files drift apart in ways nobody notices until submission.
Frameworks that govern this work
- ›CDSCO (Central Drugs Standard Control Organisation) - India
- ›ICMR National Ethical Guidelines for Biomedical and Health Research
- ›EMA requirements for EU clinical trial documentation
- ›FDA submission standards for US filings
- ›ISO 17100:2015 - independent revision by a second qualified linguist
- ›ICH-GCP principles governing trial documentation
How we run it
- ›Translators hold qualifications or documented professional experience in life sciences, not general technical translation
- ›Full Human TEP by default - translation, editing and proofreading by three separate native-language professionals, with no AI at any stage
- ›Back-translation supplied for ICF and patient-reported outcome documents, as standard rather than on request
- ›A unified glossary agreed before translation begins and enforced across every language team on the study
- ›Numerical verification as a distinct QC step, separate from linguistic review
- ›Documented audit trail from source segment to reviewer sign-off, retained for the project
Languages most requested in this sector
Demand here is not evenly spread - these come up repeatedly, and for reasons particular to the sector.
Indian scheduled languages
Trials running across multiple Indian states need the ICF in every state language, often simultaneously and to the same deadline.
Arabic dialects
Gulf trial sites need documents that read naturally to participants, not Modern Standard Arabic that feels institutional.
Central and Eastern European languages
Long-established trial site regions with strict EMA documentation requirements.
East African languages
Growing trial activity in Kenya, Uganda and Tanzania, where pharmaceutical vocabulary is least established.
Work we have done in this sector
Real projects, with the problems and the corrections described in full.
English → 9 Indian Languages: ICF Translation for a Stem Cell Transplantation Clinical Trial
A 22,000-word Informed Consent Form for a clinical trial related to stem cell transplantation, translated simultaneously into 9 Indian languages - navigating the fine line between clinical precision and participant comprehension across nine distinct scripts, with no established pharmaceutical vocabulary database available for several of the target languages.
Healthcare & Patient InformationConsistent, Clinically Accurate at Scale: English to Punjabi Patient Information Translation
A large set of pre- and post-operative patient information documents translated from English into Punjabi - and the quality framework built to catch what a fluent-sounding translation can still miss: an inconsistent term, a transposed risk statistic, or a quietly dropped safety clause.
Medical Devices (Infection Control & Disinfection)Inside a Regulated Translation Review: English to Kazakh for a Medical Device Manufacturer
A regulated Instructions for Use translation for a medical device manufacturer, from English into Kazakh - the structured, documented QA review process that catches terminology inconsistencies and mistranslations before a document reaches a hospital shelf, with real before-and-after correction examples.
Common questions
Do you provide back-translation for ICF documents?
Yes, and as standard rather than as an extra. Back-translation is produced by a linguist who has not seen the source document, then compared against the original so that meaning shifts are visible. We supply it for all ICF and patient-reported outcome work.
Is AI used anywhere in pharmaceutical translation?
No. Pharmaceutical and ICF work runs at our Full Human TEP tier, which uses no machine translation at any stage. The reason is specific: an AI translation error tends to read fluently and correctly while being wrong, which is precisely the error a reviewer is least likely to catch.
Can you handle a study running in several languages at once?
Yes - simultaneous multi-language delivery is the normal shape of this work. A recent ICF project ran to 22,000 words across nine Indian languages in parallel, with a single shared glossary maintained across all nine teams.
How do you handle terms with no equivalent in the target language?
The translator decides per term whether to translate, transliterate, or give the target term with the English in brackets - based on what a participant will actually recognise and what the reviewing authority will accept. The decision is recorded in the project glossary and applied identically across every file in the study.
Which regulatory frameworks are your translators familiar with?
CDSCO and ICMR for Indian trials, EMA requirements for EU submissions, and FDA standards for US filings. Where a submission has jurisdiction-specific formatting or mandated phrasing, that is applied at translation rather than corrected afterwards.
Have a pharmaceutical & icf project?
Tell us the document type, the languages and the deadline. We will confirm the approach and who would handle it.